Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | cannabinoid receptor 2 (macrophage) | Starlite/ChEMBL | References |
Homo sapiens | cannabinoid receptor 2 (macrophage) | References | |
Mus musculus | cannabinoid receptor 1 (brain) | Starlite/ChEMBL | References |
Mycobacterium tuberculosis | 3-dehydroquinate dehydratase AroD (AROQ) (3-dehydroquinase) (type II dhqase) | Curated by TDR Targets | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Mycobacterium tuberculosis | 3-dehydroquinate dehydratase AroD (AROQ) (3-dehydroquinase) (type II dhqase) | Get druggable targets OG5_132746 | All targets in OG5_132746 |
Mycobacterium ulcerans | 3-dehydroquinate dehydratase | Get druggable targets OG5_132746 | All targets in OG5_132746 |
Candida albicans | 3-dehydroquinase | Get druggable targets OG5_132746 | All targets in OG5_132746 |
Candida albicans | 3-dehydroquinate dehydratase | Get druggable targets OG5_132746 | All targets in OG5_132746 |
Mycobacterium leprae | 3-dehydroquinate dehydratase AroD (AroQ) (3-dehydroquinase) (Type II DHQase) | Get druggable targets OG5_132746 | All targets in OG5_132746 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Possible alanine rich transferase | 3-dehydroquinate dehydratase AroD (AROQ) (3-dehydroquinase) (type II dhqase) | 147 aa | 148 aa | 26.4 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | 3-dehydroquinate dehydratase | 0.1429 | 0.5 | 0.5 |
Mycobacterium tuberculosis | 3-dehydroquinate dehydratase AroD (AROQ) (3-dehydroquinase) (type II dhqase) | 0.1429 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | Intrinsic activity at CB1 receptor in mouse N1E-115 cells assessed as phosphorylation of ERK1/2 at 1 nM to 10 uM after 10 mins by Western blot method | LITERATURE. | 27240274 | |
Activity (functional) | 0 | Effect on upper gastrointestinal motility in CD1 mouse at 0.1 mg/kg, ip | ChEMBL. | 16279795 |
Activity (functional) | 0 | Reversal of 0.5 mg/kg WIN 55212-2-induced inhibitory effect on upper gastrointestinal motility in CD1 mouse at 0.1 mg/kg, ip | ChEMBL. | 16279795 |
Activity (functional) | = 65 % | Increase in upper gastrointestinal motility in CD1 mouse at 0.5 to 1 mg/kg, ip | ChEMBL. | 16279795 |
Activity (functional) | = 65 % | Increase in upper gastrointestinal motility in CD1 mouse at 0.5 to 1 mg/kg, ip | ChEMBL. | 16279795 |
Activity (binding) | = 102 % | Antagonist activity at CB1 receptor in mouse N1E-115 cells assessed as inhibition of WIN55,212-2-induced phosphorylation of ERK1/2 by measuring phosphorylated ERK1/2 level at 1 uM preincubated for 5 mins followed by WIN55,212-2 addition measured after 10 mins by Western blot method (Rvb = 185 +/- 12%) | LITERATURE. | 27240274 |
Intrinsic activity (binding) | = 107 % | Intrinsic activity at CB1 receptor in mouse N1E-115 cells assessed as phosphorylation of ERK1/2 at 1 uM after 10 mins by Western blot method relative to control | LITERATURE. | 27240274 |
Ki (binding) | = 0.001 nM | Displacement of [3H]CP55940 from CB1 receptor in CD1 mouse brain | ChEMBL. | 16279795 |
Ki (binding) | = 2 nM | Displacement of [3H]CP55940 from CB2 receptor in CD1 mouse spleen | ChEMBL. | 16279795 |
Ki (binding) | = 4.5 nM | Displacement of [3H]-CP55,940 from CB1 receptor in mouse whole brain membranes after 60 mins by liquid scintillation spectrometry | LITERATURE. | 27240274 |
Ki (binding) | = 28.1 nM | Displacement of [3H]-CP55,940 from human CB2 receptor transfected in CHO cell membranes after 60 mins by liquid scintillation spectrometry | LITERATURE. | 27240274 |
Ratio Ki (binding) | = 2000 | Selectivity for CB1 receptor over CB2 receptor in CD1 mouse | ChEMBL. | 16279795 |
Ratio Ki (binding) | = 2000 | Selectivity for CB1 receptor over CB2 receptor in CD1 mouse | ChEMBL. | 16279795 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.